Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 28:14:395-404.
doi: 10.2147/IJWH.S352167. eCollection 2022.

Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region

Nadia Muhaidat  1 , Mohammad A Alshrouf  2 , Muayad I Azzam  2 , Abdulrahman M Karam  2 , Majed W Al-Nazer  2 , Abdallah Al-Ani  3
Affiliations

Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region

Nadia Muhaidat et al. Int J Womens Health. .

Abstract

Background: Since the emergence of COVID-19 vaccinations, many women around the world are reporting abnormalities in their menstrual periods post-vaccination. The aim of this study is to investigate the prevalence and impact of menstrual abnormalities after the COVID-19 vaccine among females residing within the Middle East and North Africa (MENA).

Methods: The study utilized a cross-sectional online self-administered survey from July 2021 to August 2021 targeting females living in the MENA region above the age of menarche who had received vaccine and were not pregnant or lactating, and do not have a history of primary ovarian insufficiency, hypothalamic menopause, or have undergone a hysterectomy. The survey was distributed regionally via social media.

Results: A total of 2269 females were included in our study, with a mean age of 34.3 ± 8.5 years. About 66.3% of participants reported menstrual symptoms post-vaccination, of which 46.7% experienced them after their first dose. However, in 93.6% of participants, the symptoms resolved within 2 months. Vaccine type did not significantly influence the incidence of abnormalities (p > 0.05). Participants who had confirmed previous COVID-19 infection had a very similar percentage of menstrual abnormalities compared to people who did not have COVID-19 infection or symptoms suspected of COVID-19 infection and did not test (67.5%, 66.8%, respectively); nevertheless, those who had experienced the COVID-19 vaccine general side effects had significantly more abnormalities (p < 0.001). Compared to their pandemic status, females reported significantly more abnormalities post-vaccination.

Conclusion: The study showed a possible link between the COVID-19 vaccine and menstrual abnormalities that have impacted their quality of life.

Keywords: COVID-19; MENA; menstrual abnormalities; menstrual cycle; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial or personal interests that could have influenced the work reported in this paper.

Figures

Figure 1
Figure 1
Summary of the study design.
Figure 2
Figure 2
Timeline for the onset and resolution of post-vaccination symptoms.
See this image and copyright information in PMC

References

    1. Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity. 2021;54(8):1636–1651. doi:10.1016/J.IMMUNI.2021.07.017 - DOI - PMC - PubMed
    1. Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111–116. doi:10.1016/j.coi.2021.07.003 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. V-safe after vaccination health checker. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html. Accessed August 27, 2021.
    1. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–1090. doi:10.1056/NEJMoa2110475 - DOI - PMC - PubMed
    1. Locht C. Vaccines against COVID-19. Anaesthesia Crit Care Pain Med. 2020;39(6):703–705. doi:10.1016/j.accpm.2020.10.006 - DOI - PMC - PubMed